Alita A. Miller

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases · 2023 · 286 citations

Pharmacy, Infectious Diseases, Pharmacology +14

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Réville, Satenig Guler, Janelle Comita-Prevoir et al. · Nature Microbiology · 2017 · 271 citations

Life Sciences, Infectious Diseases, Microbiology +16

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell, Adam B. Shapiro, R.A. Giacobbe et al. · Antimicrobial Agents and Chemotherapy · 2015 · 247 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Spontaneous Mutations in the CsrRS Two‐Component Regulatory System of<i>Streptococcus pyogenes</i>Result in Enhanced Virulence in a Murine Model of Skin and Soft Tissue Infection

N. Cary Engleberg, Andrew Heath, Alita A. Miller et al. · The Journal of Infectious Diseases · 2001 · 198 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of <i>Neisseria gonorrheae</i>, Including Multi-Drug-Resistant Isolates

Patricia A. Bradford, Alita A. Miller, John P. O’Donnell et al. · ACS Infectious Diseases · 2020 · 145 citations · Full text

Medicine, Infectious Diseases, Pharmacology +11